Little Support For Eli Lilly's High Valuation
An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...
The price war in weight-loss drugs is here
Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...
Investing20h
Viking therapeutics director sells shares worth over $715,000
Viking Therapeutics, Inc. (NASDAQ: VKTX) director J. Matthew Singleton executed a sale of company stock valued at more than $715,000, according to a recent SEC filing. The transactions, which took ...
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.
Eli Lilly: A Strong Buy Amidst Obesity Treatment Market Dominance and Expanding Pipeline
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...
Eli Lilly & Co: Maintaining Market Dominance with Orforglipron Amid Competitor Challenges
Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...